Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Electroconvulsive Therapy

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...

Parenteral Anesthetics: Overview

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.

Depressive Disorders: MDD and Dysthymia

Depressive Disorders: MDD and Dysthymia

Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...

Depressive Disorders: Etiology

Depressive Disorders: Etiology

Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Danish SSRI deficiency or ...?].

Ugeskrift for laeger·2016

Same author

[Ketamine for treatment of acute depression].

Ugeskrift for laeger·2013

Same author

[Problems with the surveillance list].

Ugeskrift for laeger·2013

Same author

[Payment of others' stupid fines].

Ugeskrift for laeger·2013

Same author

[Clozapine card].

Ugeskrift for laeger·2011

Same author

[Free psychiatry].

Ugeskrift for laeger·2011

Same journal

[Mosaicism as a cause of Cowden syndrome].

Ugeskrift for laeger·2026

Same journal

[Thyrotoxic crisis with cardiogenic shock].

Ugeskrift for laeger·2026

Same journal

[Mindfulness-based cognitive therapy in the treatment of depression].

Ugeskrift for laeger·2026

Same journal

[Fitness].

Ugeskrift for laeger·2026

Same journal

[Risk of developing cataract related to fluoroscopy].

Ugeskrift for laeger·2026

Same journal

[Obturator hernia with small bowel ileus presenting as hip pain in an elderly woman].

Ugeskrift for laeger·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

[Ketamine in melancholic depression].

Johannes Bjerre¹, Claus Fontenay

¹Psykiatrien i Region Syddanmark, Esbjerg, Denmark. johannesbjerre@hotmail.com

Ugeskrift for Laeger

|February 12, 2010

Summary

This summary is machine-generated.

S-ketamine rapidly reduced suicidal ideation and depressive symptoms in a bipolar disorder patient. This treatment provided significant relief for five days, offering a potential therapeutic option for severe depression.

More Related Videos

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Related Experiment Videos

Last Updated: Jun 16, 2026

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Area of Science:

Neuroscience
Psychiatry
Pharmacology

Background:

Bipolar disorder is a serious mental health condition often associated with severe depressive episodes and increased suicide risk.
Major depression with melancholic and nihilistic features presents a significant treatment challenge.
Electroconvulsive therapy (ECT) is an effective treatment but requires preparation and may not offer immediate relief.

Observation:

A 35-year-old male with bipolar disorder presented with severe depression and suicidal ideation following an attempt.
The patient exhibited melancholic symptoms and nihilistic delusions, indicating a critical state.
Immediate intervention was necessary to mitigate suicide risk and alleviate profound suffering.

Findings:

Administration of S-ketamine at 0.5 mg/kg resulted in a rapid reduction of the patient's depressive symptoms and suicidal agony.
The therapeutic effects of S-ketamine were observed within two hours post-administration.
Symptomatic improvement was sustained and measurable for a period of five days.

Implications:

S-ketamine demonstrates potential as a rapid-acting agent for managing acute suicidal crises in bipolar disorder.
This finding suggests S-ketamine may serve as a valuable adjunctive therapy in the interim period before other treatments like ECT become fully effective.
Further research into S-ketamine's efficacy and safety profile for severe mood disorders is warranted.